Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 4 years or older who have been diagnosed with a type of blood cancer called B-cell non-Hodgkin lymphoma (B-cell NHL)
- People who are willing to have a blood draw and/or a small skin sample taken (a minor procedure using a small punch tool)
- People who are willing to have their full genetic information (entire DNA) analysed, including being told about findings related to the condition being studied as well as any unrelated genetic findings that may come up
Who may not be able to join:
- People who have a condition or situation that the lead doctor running the trial considers would make participation unsafe or unsuitable — examples given include certain cases where a person cannot make their own medical decisions and no family member or guardian is available to assist, or where a person is experiencing active thoughts of suicide and is considered a danger to themselves at the time of joining (confirm with trial site)
- People who do not have access to regular healthcare and a primary care doctor
- People who are currently receiving initial (induction) treatment for non-Hodgkin lymphoma
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christin Destefano, Uniformed Services University of the Health Sciences
Phone: (301) 295-3190
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Aim 1: Characterize occupational exposures and their impact on health outcomes and immune health of ADSMs and other MHS beneficiaries with B-cell NHL.; Aim 2: Identify and interpret germline variants in ADSMs and other MHS beneficiaries with B-cell NHL.; Aim 3: Create a comprehensive database and biorepository of ADSMs and other MHS beneficiaries with B-cell NHL.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.